SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?


To: 777 Captain who wrote (18249)1/28/1999 5:12:00 PM
From: Curt Whitaker  Respond to of 23519
 
They may do that later...

Off of Briefing.com...
"Vivus Inc. (VVUS) 2 15/16 unch: developer of erectile dysfunction treatments reports Q4 net of $0.03 a share, seven cents above the First Call mean estimate (3 analysts surveyed), vs a yr-ago profit of $0.17; revenue fell 66% to $11.13 mln; see press release...."



To: 777 Captain who wrote (18249)1/28/1999 5:13:00 PM
From: Andreas Samson  Read Replies (1) | Respond to of 23519
 
Alas, accounts payable exceeds cash on hand....not much room there for a stock buyback